Venus Remedies Limited (VENUSREM.BO)
INR 325.25
(-0.15%)
INR 325.25
(-0.15%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 386.8 Million INR | 0.0% |
| 2022 | 386.78 Million INR | 0.0% |
| 2021 | 386.78 Million INR | -17.41% |
| 2020 | 468.31 Million INR | -35.01% |
| 2019 | 720.53 Million INR | -37.89% |
| 2018 | 1.16 Billion INR | -15.59% |
| 2017 | 1.37 Billion INR | -15.07% |
| 2016 | 1.61 Billion INR | -15.3% |
| 2015 | 1.91 Billion INR | -5.56% |
| 2014 | 2.02 Billion INR | 44.51% |
| 2013 | 1.39 Billion INR | 8.42% |
| 2012 | 1.29 Billion INR | 30.24% |
| 2011 | 991.33 Million INR | 12.67% |
| 2010 | 879.84 Million INR | -41.1% |
| 2009 | 1.49 Billion INR | 13.52% |
| 2008 | 1.31 Billion INR | 37.48% |
| 2007 | 957.17 Million INR | 12.54% |
| 2006 | 850.48 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 386.8 Million INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 Q2 | 386.8 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 386.8 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 386.8 Million INR | 0.0% |
| 2022 Q2 | 386.8 Million INR | 0.0% |
| 2022 FY | 386.78 Million INR | 0.0% |
| 2022 Q4 | 386.78 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 386.78 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 386.79 Million INR | 0.0% |
| 2021 FY | 386.78 Million INR | -17.41% |
| 2020 FY | 468.31 Million INR | -35.01% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 480.54 Million INR | 0.0% |
| 2020 Q4 | 468.31 Million INR | 0.0% |
| 2019 Q4 | 720.53 Million INR | 0.0% |
| 2019 FY | 720.53 Million INR | -37.89% |
| 2019 Q2 | 970.28 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 FY | 1.16 Billion INR | -15.59% |
| 2018 Q4 | 1.16 Billion INR | 0.0% |
| 2017 FY | 1.37 Billion INR | -15.07% |
| 2016 FY | 1.61 Billion INR | -15.3% |
| 2016 Q4 | 1.61 Billion INR | 0.0% |
| 2015 FY | 1.91 Billion INR | -5.56% |
| 2014 FY | 2.02 Billion INR | 44.51% |
| 2013 Q4 | 1.39 Billion INR | 0.0% |
| 2013 FY | 1.39 Billion INR | 8.42% |
| 2012 Q4 | 1.29 Billion INR | 0.0% |
| 2012 Q2 | 238.98 Million INR | 0.0% |
| 2012 FY | 1.29 Billion INR | 30.24% |
| 2011 FY | 991.33 Million INR | 12.67% |
| 2010 FY | 879.84 Million INR | -41.1% |
| 2009 FY | 1.49 Billion INR | 13.52% |
| 2008 FY | 1.31 Billion INR | 37.48% |
| 2007 FY | 957.17 Million INR | 12.54% |
| 2006 FY | 850.48 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 235.2 Million INR | -64.456% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -2669.187% |
| Sigachi Industries Limited | 265.79 Million INR | -45.524% |
| Bal Pharma Limited | 363.82 Million INR | -6.315% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -246.514% |
| Medico Remedies Limited | 8.67 Million INR | -4360.332% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -262.852% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 72.432% |
| Shilpa Medicare Limited | 5.6 Billion INR | 93.095% |
| Aarti Drugs Limited | 2.75 Billion INR | 85.951% |
| Lupin Limited | 1.55 Billion INR | 75.09% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 98.188% |
| Zydus Lifesciences Limited | 251 Million INR | -54.104% |
| Windlas Biotech Limited | 20.18 Million INR | -1816.749% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Eris Lifesciences Limited | 6.54 Billion INR | 94.09% |
| Valiant Laboratories Limited | 746.63 Million INR | 48.194% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | -63.621% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 63.451% |
| Ipca Laboratories Limited | 5.8 Billion INR | 93.336% |
| Bliss GVS Pharma Limited | 355.92 Million INR | -8.675% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -2808.271% |
| Bajaj HealthCare Limited | 650.34 Million INR | 40.524% |
| RPG Life Sciences Limited | -30.3 Million INR | 1376.568% |
| Mankind Pharma Limited | 248.67 Million INR | -55.543% |
| Laurus Labs Limited | 8.6 Billion INR | 95.504% |
| Piramal Pharma Limited | 24.83 Billion INR | 98.443% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 31830.927% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 97.589% |
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 38.486% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 74.501% |
| Unichem Laboratories Limited | 382.22 Million INR | -1.198% |
| Sequent Scientific Limited | 1.42 Billion INR | 72.898% |
| Novartis India Limited | 50.7 Million INR | -662.919% |
| Wanbury Limited | 820 Million INR | 52.829% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | -82.147% |
| Wockhardt Limited | 8.91 Billion INR | 95.659% |
| Themis Medicare Limited | 267.74 Million INR | -44.469% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -411.843% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 98.779% |
| Glenmark Life Sciences Limited | 147.61 Million INR | -162.042% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 93.543% |
| Divi's Laboratories Limited | 20 Million INR | -1834.0% |
| NATCO Pharma Limited | 53 Million INR | -629.811% |
| Gufic Biosciences Limited | 1.53 Billion INR | 74.877% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 96.168% |
| Procter & Gamble Health Limited | 68.8 Million INR | -462.209% |
| FDC Limited | 2.46 Million INR | -15585.32% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 78.921% |
| Granules India Limited | 689.71 Million INR | 43.918% |
| Medicamen Biotech Limited | 12.55 Million INR | -2980.844% |
| Alkem Laboratories Limited | 400 Million INR | 3.3% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -1289.567% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -10749.93% |
| Megasoft Limited | 1.35 Billion INR | 71.497% |
| ZIM Laboratories Limited | 356 Million INR | -8.65% |
| Strides Pharma Science Limited | 6.71 Billion INR | 94.24% |
| Neuland Laboratories Limited | 449.2 Million INR | 13.893% |
| Morepen Laboratories Limited | 33.64 Million INR | -1049.822% |
| Hikal Limited | 4.22 Billion INR | 90.853% |
| Indoco Remedies Limited | 3.51 Billion INR | 89.003% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -96600.0% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | -189.649% |
| Hester Biosciences Limited | 1.81 Billion INR | 78.721% |